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SUMMARY
IgG and IgG3 antibodies to merozoite surface protein-2
(MSP-2) of Plasmodium falciparum have been associated
with protection from clinical malaria in independent studies.
We determined whether this protection was allele-specific by
testing whether children who developed clinical malaria
lacked IgG⁄IgG3 antibodies specific to the dominant msp2
parasite genotypes detected during clinical episodes. We
analysed pre-existing IgG and IgG1⁄IgG3 antibodies to anti-
gens representing the major dimorphic types of MSP-2 by
ELISA. We used quantitative real-time PCR to determine
the dominant msp2 alleles in parasites detected in clinical
episodes. Over half (55%, 80⁄146) of infections contained
both allelic types. Single or dominant IC1- and FC27-like
alleles were detected in 46% and 42% of infections respec-
tively, and both types were equally dominant in 12%. High
levels of IgG⁄IgG3 antibodies to the FC27-like antigen were
not significantly associated with a lower likelihood of clinical
episodes caused by parasites bearing FC27-like compared to
IC1-like alleles, and vice versa for IgG⁄IgG3 antibodies to
the IC1-like antigen. These findings were supported by
competition ELISAs which demonstrated the presence of IgG
antibodies to allele-specific epitopes within both antigens.
Thus, even for this well-studied antigen, the importance of an
allele-specific component of naturally acquired protective
immunity to malaria remains to be confirmed.
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INTRODUCTION
Evidence from experimentally induced malaria and epide-
miological observations has been generally considered to
support the idea that immunity to malaria is to an impor-
tant extent ‘strain specific’ (1–3). While the concept of a
malaria ‘strain’ remains contentious (4), there is evidence
in animal models that the protection afforded by immuni-
zation with antigens encoded by polymorphic single locus
genes is largely allele-specific (5,6). The implications are
that sub-unit vaccines based on only one allelic type might
protect against a fraction of the parasite population, and
thus select for parasites bearing alternative alleles. This
outcome was suggested in a phase IIb trial of the combi-
nation B malaria vaccine which contained the 3D7-like
allele of merozoite surface protein-2 (MSP-2), and where
subsequent infections in vaccinees had a preponderance of
parasites bearing the alternative FC27-like alleles, support-
ing the rationale for incorporating the major allelic types
of polymorphic antigens in malaria vaccine development
(7).
We have previously shown that high levels of naturally
acquired IgG antibodies to MSP-2 are strongly associated
with protection against clinical malaria in two independent
cohorts of Kenyan children (8). Here, we investigated
whether this protection is specific in relation to the major
allelic dimorphisms of msp2 in the sub-set of children who
subsequently presented to hospital with malaria. We also
determined whether the protective anti-MSP-2 antibodies
were of the IgG1 or IgG3 sub-classes.
MATERIALS AND METHODS
Patient samples
A case–control study of clinical malaria in which antibod-
ies to a panel of Plasmodium falciparum merozoite anti-
gens including MSP-2 were analysed in children aged
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  2010 Blackwell Publishing Ltd 1931–5 years in Kilifi, Kenya has been reported in detail pre-
viously, and included 165 cases and 298 controls (8). This
study focuses on the cases (n = 165) who presented to hos-
pital with either mild or severe malaria, and for whom
parasite DNA was available from this acute clinical epi-
sode (N = 146, mild malaria n = 71, severe malaria
n = 75). All antibodies were assayed in serum samples col-
lected during a cross-sectional survey at the start of a
malaria transmission season in May 1995. As the antibod-
ies were collected before the clinical episodes, they are
referred to as ‘pre-existing’ antibodies. Parasite DNA was
collected from subsequent samples collected when children
presented to hospital with acute clinical malaria. Ethical
approval was granted by the Kenya National Research
Ethics Committee.
Parasite genotyping by real-time quantitative PCR
(RTQ-PCR)
Design of msp-2 family specific primers
Merozoite surface protein-2 sequences of P. falciparum
contain a central domain comprised of repeats that vary
in number, length and sequence, flanked in turn by nonre-
petitive variable sequences, and by conserved N- and C-
terminal domains. Dimorphic, nonrepetitive sequences
internal to the N- and C-termini distinguish the two main
allelic families (3D7⁄IC1-like or ‘type A’ and FC27-like or
‘type B’) (9). For simplicity and clarity, these two allelic
families will henceforth be referred to as type A or type B.
Primers were designed to amplify dimorphic regions close
to the C-terminus using Primer Express Version 3Æ0
(Applied Biosystems, Warrington, UK), using sequences
from a type A-like parasite (accession number U91677)
and a type B-like parasite (accession number EU647454).
The forward and reverse primers for type A alleles were
MSP2ICF: 5¢-CCCACTCAAGATGCAGACACTAA-3¢
and MSP2ICR: 5¢-TGGAGCAGAATTTTCAGCTTGTT-
3¢, respectively, while those for type B alleles were
MSP2FCF 5¢-GCACCAAATAAAACAGACGGTAAAG-
3¢ and MSP2FCR 5¢-GGTCCTTCTTCAGTTGATT-
CATTTAAT-3¢, respectively.
Real-time quantitative PCR
Reactions were performed using the 7500 Real-Time PCR
System (Applied Biosystems). Twenty-five microlitre reac-
tions were set-up in 96 well optical plates (Applied Bio-
sytems) using Quantitect SYBR Green PCR Master Mix
(Qiagen, Crawley, UK), 100 nM primers (SIGMA, Dorset,
UK), 1 lL of template and the ROX
TM dye for detection.
Initial amplification steps were 50 C for 2 s then 95 Cf o r
10 s, followed by 40 cycles of 95 C for 15 s and 60 Cf o r
1 min, then a dissociation step of 95 C for 15 s and 60 C
for 1 min, with a final post-dissociation cooling step of
95 C for 15 s. The dissociation step was used to exclude
contamination and to determine the dissociation tempera-
tures of the amplicons. The expected amplicon sizes were 65
and 76 base pairs for the msp2 type A and type B alleles,
respectively. The default threshold setting of 0Æ2 was used to
analyse all the data. The average amplification efficiency
was determined from the slope of the standard curve for
each reaction using the equation E =1 0
()1 ⁄ slope))1.
Preparation of genomic DNA standards for RTQ-PCR
Laboratory cultures of P. falciparum clones ‘Malayan
Camp’ (MC, type A at the msp2 locus) and ‘Dd2’ (type B
at the msp2 locus) were grown to 5–10% parasitaemia. A
total of 100 lL of each of the culture media (20 lL pellet)
was used to extract parasite genomic DNA using DNA
Qiamp mini-kits (Qiagen, UK). The amount of genomic
DNA was quantified by UV spectrophotometry and
adjusted to 10 ng⁄lL for each of the two standards. Ten-
fold serial dilutions were then prepared for each (MC and
Dd2), in the range of 10–0Æ00001 ng and were run sepa-
rately for each allelic type on each plate to enable compar-
able quantification of each major allelic type.
Preliminary experiments with mixed clone infections
To determine the accuracy of the method for quantifica-
tion of the major dimorphic types of msp2 from patient
samples, mixtures of MC and Dd2 parasite cultures were
prepared in the following ratios, with a final volume of
100 lL for each set: 100 : 0; 99Æ5:0 Æ5; 99 : 1; 90 : 10;
50 : 50; 10 : 90; 99 : 1; 99Æ5:0 Æ5; 0 : 100. A similar design
has been reported previously for quantification of rodent
malaria parasite genotypes (10). Parasite genomic DNA
was then extracted from each of these blood mixtures as
described above before analysis by RTQ-PCR including
no-template negative controls and a positive control.
Seryl-tRNA synthetase is conserved in P. falciparum (11)
and was tested in parallel as the positive control using
published primers, PF07_0073 (12). The reproducibility or
between-run variation of the assay was checked and con-
firmed by testing each of the mixtures with each primer
pair in multiple independent runs. The coefficient of varia-
tion (%) was calculated as the (row or average standard
deviation⁄mean) · 100 (10).
Parasite genotyping of patient samples
Frozen parasite isolates were thawed and cultured for one
cycle using standard techniques from the ring to the schi-
zont stage, to bulk up parasite DNA for extraction using
the DNA Qiamp mini-kits (Qiagen). Genomic DNA from
each sample was amplified by RTQ-PCR in separate
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type B alleles. Standards for each allelic family were run
simultaneously on each plate for quantification. Samples
were considered positive, if they contained >0Æ001 ng⁄lL
of genomic DNA. This threshold was the lowest amount
that could be reproducibly detected as determined from
the standard curves run on each plate. Samples were con-
sidered to be dominant for one allelic type, if they con-
tained at least double the amount of the alternative allelic
type. The proportions of either allelic type of genomic
DNA were calculated from the total amount of DNA
detected in ng⁄lL from each allele-specific reaction. These
experiments were designed to detect the dominant msp2
allelic families and not the absolute number of clones.
Recombinant antigens and ELISA
Detailed methods for expression, purification and charac-
terization of the recombinant proteins used in this study
are published. Both MSP-2 antigens were expressed in
Escherichia coli fused to a Glutathione S-transferase
(GST) sequence for purification, and each represents a
major allelic type of MSP-2 (MSP-2_CH150⁄9 (type A)
and MSP-2_Dd2 (type B)) (13), and the GST portion was
also expressed alone as a control for background antibody
reactivity. For simplicity and clarity, these antigens will
henceforth be referred to as type A and type B antigens.
The total IgG ELISA assays were performed using a
standard protocol, and results on the children with severe
malaria (n = 89) have been reported as part of a previous
analysis (8). Thresholds for characterizing IgG antibody
reactivity as ‘high level’ had been derived previously as the
antibody ELISA OD level above which the risk of disease
was lower than the population’s average risk (OD > 0Æ620
and 0Æ712 for the MSP-2 type A and B antigens, respec-
tively) (8). Sero-positivity for total IgG was defined as an
ELISA OD value above the mean plus three standard
deviations of the values for negative control sera from 40
nonmalaria exposed donors from the United Kingdom.
For the type A antigen, the cut-off for sero-positivity was
an ELISA OD of 0Æ101, with a median of 0 (range
0–0Æ0859). For the type B antigen, the cut-off for sero-
positivity was an ELISA OD of 0Æ109, with a median of 0
(range 0–0Æ098).
Competition ELISA assays were performed on selected
samples to detect total IgG antibodies directed against
allele-specific as opposed to conserved epitopes (shared
between alleles). Diluted sera were pre-incubated with an
excess (1000 ng) of competing heterologous antigens for
5 h, before addition to each ELISA plate well coated with
50 ng of homologous antigens and subsequent perfor-
mance of the ELISA in the standard method. This
ensured that only IgG antibodies to allele-specific epitopes
of the homologous antigen were detected, while those to
conserved epitopes would have been absorbed in the pre-
incubation step. As a control, an aliquot of the same
serum sample was also pre-incubated with an excess
(1000 ng) of homologous antigen, before addition to
ELISA plates containing 50 ng of the same antigen. The
average ELISA OD in the homologous competition assays
was 0Æ156 for the type A antigen and 0Æ221 for the type B
antigens. The median difference in ELISA OD between
heterologous and homologous competition assays was
0Æ510 (range 0Æ014–1Æ920) for the type A antigen, and
0Æ386 (range )0Æ117 to 1Æ918) for the type B antigen. A
difference of >0Æ3 ELISA OD units between the hetero-
logous and homologous absorption assays was considered
to indicate substantial allele-specific reactivity (14). IgG
sub-class ELISA assays were identical to those for total
IgG except horseradish peroxidase (HRP)-conjugated
polyclonal sheep antibodies specific for human IgG1 and
IgG3 (The Binding Site, Birmingham, UK) were used as
secondary antibodies at a 1⁄3000 dilution.
Statistical analysis
Logistic regression was used to examine the effect of sero-
positivity (or high levels) of total IgG to each MSP-2 anti-
gen on the odds of getting a clinical episode caused by
parasites bearing the corresponding homologous parasite
alleles, compared with parasites bearing the alternative
heterologous alleles. Analyses were conducted first for sin-
gle allele infections and then repeated including children
in whom a single dominant allelic type was detected. In
separate analyses, the proportions of children who were
sero-positive (or had high levels of IgG antibody) to each
antigen were compared amongst children in whom a single
or dominant corresponding allelic type was detected.
The effects of high levels of IgG1 and IgG3 antibodies
against each of the MSP-2 antigens on the risk of clinical
disease were analysed using modified Poisson regression
models as previously described (8). These analyses were
conducted on the entire data set (cases and controls), as
had been previously reported for total IgG antibodies to
MSP-2 (8). The results are reported as relative risks (RR)
with 95% confidence intervals (95% CI) and P-values.
RESULTS
Parasite genotyping by RTQ-PCR
The specificity of the primers for the major allelic families
of msp2 was confirmed by conducting cross-reaction tests,
where type A genomic DNA (MC) was amplified with
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(Dd2) amplified with type A primers], with positive and
negative controls. Type A genomic DNA was only ampli-
fied by type A primers and the positive control primers,
but not by type B primers. Similarly, type B genomic
DNA was only amplified by type B primers and the
positive control primers, but not by type A primers. The
dissociation curves for each allelic type showed single,
allele-specific peaks free of contamination. Preliminary
experiments in which laboratory cultured parasites of
either msp2 allelic type were mixed in known proportions
were highly reproducible on four independent runs
(Figure 1). The threshold cycle (Ct) reflects the cycle num-
ber when fluorescence generated within a reaction reaches
the threshold and is inversely proportional to logarithm of
the initial copy number. Figure 1 (left panel) shows that as
the proportion of MC parasites in the mixture decreased
the Ct increased proportionally, while Figure 1 (right
panel) shows that as the proportion of Dd2 parasites in
the mixture increased, the Ct decreased proportionally.
The average coefficients of variation for four independent
runs were 2Æ68% for type A assays and 0Æ35% for type B
assays. The amplification efficiency was determined from
the standard curves on each plate and was >98% for both
type A and type B reactions indicating that there was no
amplification bias for either allelic type.
Proportion of isolates containing each of the major msp2
alleles
Data on parasite genotypes was available for 146⁄165
study children who had a clinical episode of malaria. Par-
asite material was collected at the time of presentation to
hospital with an acute clinical episode of malaria. One
sample was negative by RTQ-PCR for both msp2 allelic
types as well as the positive control. Table 1 shows the
proportions of msp2 alleles detected by RTQ-PCR.
Although type A msp2 alleles were more common (i.e.
proportion positive) than type B alleles, this was not sig-
nificant (82% vs. 72%, P =0 Æ063). A single allelic type
was detected in 45% of the samples, while the remainder
contained both type A and type B alleles. Neither allelic
type was over-represented amongst children presenting
with mild or severe malaria (proportion with type A, 83%
vs. 81% and type B, 70 vs. 73%, for mild and severe
malaria, respectively). There was no bias in the distribu-
tion of either allele amongst all age groups of children
(analysed in 1 year categories from 1 to 5 years). Domi-
nant (including single) type A alleles were detected in 46%
(67⁄146) of samples, while dominant type B alleles were
detected in 42% (61⁄146) of samples. Neither allelic type
was dominant in children presenting with mild or severe
malaria, or in any particular age category. A dominant
allelic type (defined as at least double the amount of the
alternative allelic type) could not be confidently distin-
guished in a minority of samples, 18⁄146 (12%).
Prevalence of total IgG antibodies to MSP-2
Antibodies were analysed in samples collected during a
cross-sectional survey at the start of a malaria trans-
mission season. This was before the children presented
with acute clinical episodes. Overall, the IgG antibody
Figure 1 Genomic DNA extracted from
laboratory cultures containing known
mixtures of parasites bearing type A or
type B msp2 alleles was assayed by QRT-
PCR using primers for type A and type B
alleles. Left panel: as the proportion of
type A bearing parasites decreased, the
Ct increased proportionally. Right panel:
as the proportion of type B bearing para-
sites increased, the Ct decreased propor-
tionally. Error bars indicate the standard
deviations for four independent runs.
Table 1 Number of isolates containing each of the major msp2
alleles
Type A
Type B
Total 01
0 1 25 26
1 40 80 120
Total 41 105 146
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and reflected the prevalence of the msp2 allelic types
(above). The prevalence of IgG sero-positivity was 65%
(95⁄146) for the type A antigen and 65% (95⁄146) for the
type B antigen, while that of high level IgG antibodies
was 20% (29⁄146) and 25% (37⁄146) for the type A and B
antigens, respectively. Total IgG antibodies to the type A
and B antigens were highly correlated, pairwise correlation
coefficient P =0 Æ67, P <0 Æ001, and only a minority of
children showed clear allele-specific IgG antibody reactiv-
ity when antibodies to full-length MSP-2 antigens were
examined by indirect ELISA (Figure 2). Total IgG anti-
body levels to the MSP-2 type A and B antigens increased
significantly with age (P =0 Æ020 and P =0 Æ004, respec-
tively).
IgG3 antibodies to MSP-2 are associated with protection
from clinical malaria
We had previously reported that total IgG antibodies to
MSP-2 were strongly associated with protection from clini-
cal malaria in this population (8). We further analysed
these samples to determine whether this protection was
mediated by antibodies of the IgG1 or IgG3 sub-classes.
For the MSP-2 type A antigen, IgG3 sub-class antibodies
predominated over IgG1 antibodies (Wilcoxon matched-
pairs sign-rank test z = )7Æ3, P <0 Æ001), while for the
MSP-2 type B antigen the distributions of IgG1 and Ig3
antibodies were similar (Wilcoxon matched-pairs sign-rank
test z =0 Æ5, P =0 Æ587). We found that IgG3 antibodies to
both the type A and B antigens were significantly associ-
ated with protection from clinical malaria, while IgG1
antibodies to both antigens were not. Children with high
levels of IgG3 to the MSP-2 type A and B antigens were
significantly less likely to develop clinical disease than
those with low levels, RR 0Æ35 (95% CI 0Æ14–0Æ88)
P =0 Æ026, and RR 0Æ22 (95% CI 0Æ08–0Æ60) P =0 Æ003,
respectively. In contrast, children with high levels of IgG1
to the type A antigen were not protected from clinical
malaria when compared to those with low levels (RR 1Æ04
(95% CI 0Æ56–1Æ93) P =0 Æ885). Although children with
high levels of IgG1 to the type B antigen were less likely
to develop clinical malaria than those with low levels, this
was not significant [RR 0Æ57 (95% CI 0Æ30–1Æ12)
P =0 Æ108].
Total IgG, IgG1 and IgG3 antibodies to the major
allelic MSP-2 antigens do not appear to protect in an
allele-specific manner
If antibodies conferred protection in an allele-specific
manner, it might be expected that antibodies to the type A
MSP-2 antigen would protect against clinical episodes
caused by parasites bearing homologous type A as
opposed to type B msp2 alleles. We therefore investigated
whether children sero-positive for type A IgG antibodies
were less likely to be infected with parasites containing
type A compared to type B alleles, than sero-negative chil-
dren and vice versa for type B IgG antibodies and alleles
(Table 2). To account for the fact that children living in
malaria-endemic areas commonly harbour parasites
asymptomatically and therefore parasites detected may not
be causally responsible for clinical episodes, we conducted
two separate analyses. The first considered only those in
whom a single allelic type was detected, while the second
additionally included those in whom a dominant allelic
type was detected. As previous analyses in this cohort of
children demonstrated that defining a threshold for high
vs. low level IgG antibodies allowed a robust prediction of
children who were subsequently protected from clinical
malaria (8), we repeated the above analyses using this
threshold in place of sero-positivity.
Pre-existing type A IgG antibodies did not protect
against clinical episodes caused by parasites bearing type
A as opposed to type B msp2 alleles. This was true both
for single allele infections and infections in which domi-
nant alleles were additionally considered (Table 2). Chil-
dren with pre-existing type B IgG antibodies were not
significantly less likely to present with clinical episodes
caused by parasites bearing type B as opposed to type A
alleles (Table 2). These results did not change when the
Figure 2 Correlation between IgG antibody reactivity to MSP-2
type A and B antigens. Dashed lines indicate cut-off values for
sero-positivity, while solid lines indicate cut-off values for high
levels of antibodies. Pairwise correlation coefficient was 0Æ67,
P <0 Æ001 (n = 146).
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same data were analysed using IgG1 and IgG3 antibodies,
there was also no evidence that either of these IgG sub-
classes protected against clinical episodes with parasites
bearing homologous as opposed to heterologous alleles.
In a separate analysis, we considered whether children
presenting with single or dominant (single plus dominant)
type A infections were often sero-negative for the corre-
sponding type A IgG antibodies, and vice versa for type B.
This relationship was not observed (Table 3, top panel).
Similarly, children presenting with type A alleles had low
levels of pre-existing type A IgG antibodies, but also had
low levels of pre-existing type B antibodies. Likewise, chil-
dren presenting with type B alleles had low levels of pre-
existing type B IgG antibodies, but also had low levels of
pre-existing type A IgG antibodies. These findings indicate
that the lack of protection was not allele-specific (Table 3,
bottom panel). Similar results were obtained, when the
data were stratified for severe or mild malaria. When these
data were analysed using IgG1 and IgG3 sub-class anti-
bodies, children presenting with either type A or type B
infections were often sero-negative or had low levels of
antibodies to both antigens, indicating that the lack of
protection was not allele-specific.
Competition ELISA confirms the presence of antibodies
to allele-specific epitopes
It may be argued that because full-length antigens utilized
in this study contain allele-specific as well as conserved
epitopes, the contribution of allele-specific epitopes per se
to protection cannot be directly ascertained. To address
this, we selected children whose clinical episodes were
Table 2 Logistic regression for the effect of type A (or B) MSP-2
IgG antibodies on clinical episodes caused by parasites bearing
homologous vs. heterologous alleles
Antibodies
Single allele
infections
Single and dominant
allele infections
Odds ratio
95% CI
P-
value
Odds ratio
95% CI
P-
value
Sero-positive A 0Æ84 (0Æ30–2Æ37) 0Æ747 1Æ07 (0Æ52–2Æ23) 0Æ837
High level A 2Æ88 (0Æ55–14Æ81) 0Æ207 1Æ96 (0Æ80–4Æ81) 0Æ140
Sero-positive B 0Æ76 (0Æ27–2Æ11) 0Æ603 1Æ20 (0Æ58–2Æ48) 0Æ608
High level B 0Æ44 (0Æ12–1Æ57) 0Æ209 0Æ53 (0Æ23–1Æ21) 0Æ134
For type A IgG antibodies, the odds ratios indicate the protective
effects of sero-positivity for (or high levels of) type A IgG anti-
bodies on clinical episodes with parasites bearing type A as
opposed to B alleles. Similarly, for type B IgG antibodies, the
odds ratios indicate the protective effects of sero-positivity for (or
high levels of) type B IgG antibodies on clinical episodes with
parasites bearing type B as opposed to A alleles. Single allele
infections, n = 65 (40 type A and 25 type B alleles, respectively).
Single and dominant clone infections, n = 128 (67 type A and 61
type B alleles, respectively).
Table 3 Prevalence of sero-positivity or high level IgG antibodies for MSP-2 antigens amongst children with a single or dominant msp2
major allelic type
msp2 allelic type
MSP-2 antibodies
Sero-positive A
n (%)
Sero-negative A
n (%)
Sero-positive B
n (%)
Sero-negative B
n (%)
Single type A alleles (n = 40) 24 (60) 16 (40) 25 (62Æ5) 15 (37Æ5)
Single type B alleles (n = 25) 16 (64) 9 (36) 14 (56) 11 (44)
Dominant type A alleles (n = 67) 44 (66) 23 (34) 41 (61) 26 (39)
Dominant type B alleles (n = 61) 39 (64) 22 (36) 40 (66) 21 (34)
msp2 allelic type
High level A
n (%)
Low level A
n (%)
High level B
n (%)
Low level B
n (%)
Single type A alleles (n = 40) 8 (20) 32 (80) 12 (30) 28 (70)
Single type B alleles (n = 25) 4 (16) 21 (84) 2 (8) 23 (92)
Dominant type A alleles (n = 67) 17 (25) 50 (75) 21 (31) 46 (69)
Dominant type B alleles (n = 61) 9 (15) 52 (85) 12 (20) 49 (80)
Similar proportions of children with single or single plus dominant allele type A or B infections were sero-positive for pre-existing type A
and type B IgG antibodies, respectively. Children infected with type A or B alleles had low levels of IgG antibodies to the homologous
antigen, but also had similarly low levels of IgG antibodies to the heterologous antigen, indicating that the lack of protection was not
allele-specific.
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msp2 allelic type and who had high levels of pre-existing
IgG antibodies to the homologous MSP-2 antigen. We per-
formed competition ELISAs on these sera to verify that
they contained IgG antibodies to allele-specific epitopes
within the MSP-2 antigens. Sixteen children had high levels
of pre-existing IgG antibodies to MSP-2 type A and subse-
quent clinical episodes caused by type A parasites. Compe-
tition with excess of the type B antigen revealed that 13⁄16
children had IgG antibodies to allele-specific epitopes
within the type A antigen. Eleven children had high levels
of pre-existing IgG antibodies to the type B antigen and
subsequent clinical episodes caused by type B parasites.
Competition with excess of the type A antigen revealed
that 8⁄11 children had IgG antibodies to allele-specific epi-
topes within the type B antigen. Thus, the majority of
these children developed clinical episodes despite having
allele-specific IgG antibodies homologous to the major
allelic types of the parasites that infected them.
DISCUSSION
Studies conducted in different populations have shown
that serum IgG or IgG3 antibodies to the blood stage
antigen MSP-2 of P. falciparum were associated with pro-
tection from clinical episodes of malaria (8,13,15). This
antigen is encoded by a polymorphic single locus gene and
there is strong evidence that antigenic diversity has been
driven by immune pressure (16). Along with this, the
combination B malaria vaccine trial provided the first
proof-of-principle of vaccine-induced selection on malaria
parasites in humans (7).
Children and adults in malaria-endemic areas com-
monly harbour asymptomatic parasitaemias, comprising
complex mixtures of distinct parasite clones, which fluctu-
ate over months, weeks, and even days (3,17). These longi-
tudinal studies have also shown that clinical episodes are
often associated with an abrupt increase in parasite densi-
ties (1) in which novel parasite clones are commonly
detected (1,18,19), consistent with the idea of ‘strain’-
specific immunity, limiting the growth of some, but not all
parasites (20). We therefore used quantitative real-time
PCR to determine the dominant parasite genotype detect-
able (10), with the cautious assumption that it was caus-
ally responsible for the clinical episode of malaria.
In the population studied here, we previously found that
high levels of IgG antibodies to MSP-2 were strongly associ-
ated with protection against clinical malaria (8). Further
analyses revealed that this protection was mediated by anti-
bodies of the IgG3 and not the IgG1 sub-class. In this study,
we analysed the sub-group of children who subsequently
developed clinical episodes to determine whether antibodies
conferred protection in an allele-specific manner. In this
sub-group of children, neither pre-existing total IgG, nor
IgG1⁄IgG3 antibodies differentially protected against para-
sites bearing homologous as opposed to heterologous msp2
alleles. For total IgG antibodies, the presence of antibodies
to allele-specific epitopes was confirmed by competition
ELISAs, and supported the finding that protection was not
mediated in an allele-specific fashion. These findings concur
with those recently reported from Papua New Guinea where
although IgG1 and IgG3 antibodies to both type A and B
antigens were associated with protection, it was not allele-
specific. While the majority of infections were caused by
parasites bearing type A alleles, high levels of IgG1 and
IgG3 antibodies to the type B antigen (as well as the type A
antigen) protected against symptomatic episodes caused by
type A parasites (21).
While many studies have examined the infecting MSP-2
parasite genotype and the corresponding allele-specific
antibody response, these have been performed in concur-
rent samples (22–24) or in acute-convalescent pairs of sam-
ples (25,26). To our knowledge only one study has analysed
naturally acquired allele-specific IgG antibodies to MSP-2
and protection from clinical malaria, albeit using a slightly
different end-point (27). This study was conducted
amongst adults in the Brazilian Amazon who were exposed
to low levels of P. falciparum transmission. Although the
sample size was limited, they found that pre-existing allele-
specific IgG antibodies did not predict clinical outcome in
infections with parasites bearing homologous rather than
heterologous msp2 alleles. Clinical outcome was defined as
the prevalence or severity of symptomatic infections,
though none of their study participants developed severe
malaria during follow-up (27). A limitation of our study is
that we did not assay the fine levels of allele-specificity to
the many variants or sub-types of the major allelic families
of MSP-2 (28). Rather, we concentrated on the concern
that vaccine-induced immunity may be limited by specific-
ity at the level of major allelic types. We found little evi-
dence that this was the case for naturally acquired
protective responses in this population. Another potential
limitation is that our competition ELISAs were performed
with total IgG antibodies, rather than with the IgG3
sub-class antibodies which were specifically associated with
protection. On the other hand, we found no evidence that
pre-existing IgG3 antibodies conferred protection in an
allele-specific manner in this sub-group of children.
Taken together, these data show that although pre-
existing IgG⁄IgG3 antibodies to antigens representing the
major dimorphic types of MSP-2 are strongly associated
with a reduced incidence of clinical malaria in the major-
ity of children (8), a minority still develop disease despite
having had not only high level antibodies, but also
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This minority of children may not be the ideal group to
study as they represent the ‘failures’, in whom putatively
‘protective’ anti-MSP-2 antibodies failed to protect.
Another potential explanation for this result is the time to
presentation to hospital with an acute clinical episode
which varied widely in our study, mean 139 days (range 7–
274). Given the half life of IgG antibodies to several
malaria antigens including MSP-2 may be short in young
children in endemic areas (29,30), it is likely that the levels
of antibodies had declined significantly by the time the
clinical episode developed. However, one would expect
that memory B cells of the corresponding specificity would
remain. All the same, antibodies measured at a single time
point have been a robust predictor of the risk of clinical
malaria in numerous immuno-epidemiological studies,
including the cohort from which the children in this study
were drawn (8). Alternatively, the antibodies were present
but lacked the functional capacity to control the infection
and subsequent clinical presentation. Another possibility
is that the intrinsically unstructured nature of MSP-2
makes it difficult to accurately detect antibody reactivity
to various parts of the protein using ELISA techniques
with GST fusion proteins (31).
These data should be considered in the context of the
evidence for immune selection on parasite diversity (16)
and the paradigm of ‘strain’ specific immunity being
important in protection from malaria. While the loci used
to detect the presence of distinct parasite clones or
‘strains’, are often identical to those that encode for anti-
gens that are considered as targets of protective immunity
(e.g. MSP-1 block 2, MSP-2 and MSP-3), ‘strain’-specific
immunity is not synonymous with allele-specific immunity,
the latter at best being a ‘sub-set’ of the former. Nonethe-
less, when protective antibody responses are directed to
polymorphic antigens, it might be expected that the poly-
morphism is driven by immune pressure and that protec-
tion would be greater against disease episodes caused by
parasites bearing homologous alleles. It is possible that
the differential allele-specific protection necessary to main-
tain diversity in the population need only be marginal and
could not be detected in this kind of study. Alternatively,
signatures of selection on polymorphic parts of antigens
may identify them as targets of protective immunity, but
do not necessarily indicate that they are more important
targets than adjacent sequences in the same proteins that
may be conserved for functional reasons. Protective immu-
nity might be directed against conserved sequences within
antigenically diverse proteins. This would be welcome news
for malaria vaccine development and needs to be con-
firmed in larger studies, as well as in other malaria trans-
mission settings.
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